When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ALXN - Apellis Pharmaceuticals: Will Soliris Finally Have Some Competition?
Alexion Pharmaceuticals Inc.
At $508,000 per patient per year, Alexion Pharmaceuticals' (ALXN) Soliris (eculizumab) is the most expensive drug in the world. There have been many efforts to replicate the efficacy of the most expensive drug in the world without that high price tag. These efforts have taken the forms of having an MOA similar to eculizumab but with better dosing regimen (ULTOMIRIS from Alexion, but quite a high price tag as well), targeting an alternative pathway instead of the C5 pathway targeted by Soliris (OMS721 targeting Lectin) and so on.